ArticleAdvances in therapy2025

Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.

Cristina Arriens et al.PubMed ↗Publisher ↗

No numbers read from the abstract.